- Home
- SCNX vs KTTA Comparison
SCNX vs KTTA Comparison
Compare SCNX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | KTTA |
|---|---|---|
| Founded | 2010 | 2020 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 18.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SCNX | KTTA |
|---|---|---|
| Price | $0.47 | $0.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 2.1M | 126.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $347.88 | N/A |
| Revenue Next Year | $744.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.28 |
| 52 Week High | $3.17 | $2.34 |
Technical Indicators
Market Signals| Indicator | SCNX | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 56.24 | 50.24 |
| Support Level | $0.47 | $0.78 |
| Resistance Level | $0.60 | $0.84 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 54.71 | 59.80 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).